Artax Biopharma Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 9

Artax Biopharma General Information

Description

Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. The company's drugs eliminate harmful foreign pathogens while being tolerant of self-tissues and organs that simultaneously allow the body to fight foreign pathogens, enabling doctors to treat both the symptoms and the underlying disease with fewer side effects.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1 Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (617)

Artax Biopharma Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Artax Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Accelerator/Incubator Completed Clinical Trials - Phase 2
6. Later Stage VC 06-Aug-2024 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 11-May-2022 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B3) 29-Apr-2020 Completed Pre-Clinical Trials
3. Later Stage VC (Series B2) 08-Aug-2019 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 22-Sep-2015 $10M $12M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 10-Nov-2014 $2.01M $2.01M Completed Pre-Clinical Trials
To view Artax Biopharma’s complete valuation and funding history, request access »

Artax Biopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B4
Series B3
Series B2
Series B 8,750,452 $0.000100 $0.09 $1.14 $1.14 1x $1.14 14.79%
Series A 2,805,396 $0.000100 $1.77 $1.77 1x $1.77 4.74%
To view Artax Biopharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Artax Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. The company's drugs eliminate
Drug Discovery
Cambridge, MA
11 As of 2022

Paris, France
 

Pasadena, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Artax Biopharma Competitors (23)

One of Artax Biopharma’s 23 competitors is Abivax, a Formerly PE-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abivax Formerly PE-Backed Paris, France
Meditope Biosciences Venture Capital-Backed Pasadena, CA
Equillium Formerly VC-backed La Jolla, CA
Immunophotonics Private Equity-Backed Saint Louis, MO
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 23 competitors. Get the full list »

Artax Biopharma Patents

Artax Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3759086-A1 Chromene derivatives as inhibitors of tcr-nck interaction Pending 27-Feb-2018
US-11008310-B2 Chromene derivatives as inhibitors of tcr-nck interaction Active 27-Feb-2018
US-10696663-B2 Chromene derivatives as inhibitors of tcr-nck interaction Active 27-Feb-2018
US-20200347042-A1 Chromene derivatives as inhibitors of tcr-nck interaction Active 27-Feb-2018
US-20190263792-A1 Chromene derivatives as inhibitors of tcr-nck interaction Active 27-Feb-2018 C07D311/58
To view Artax Biopharma’s complete patent history, request access »

Artax Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Artax Biopharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Dosbio50 Venture Capital Minority
Eli Lilly Corporation Minority
Sound Bioventures Venture Capital Minority
Columbus Venture Partners Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Artax Biopharma FAQs

  • When was Artax Biopharma founded?

    Artax Biopharma was founded in 2013.

  • Where is Artax Biopharma headquartered?

    Artax Biopharma is headquartered in Cambridge, MA.

  • What is the size of Artax Biopharma?

    Artax Biopharma has 11 total employees.

  • What industry is Artax Biopharma in?

    Artax Biopharma’s primary industry is Drug Discovery.

  • Is Artax Biopharma a private or public company?

    Artax Biopharma is a Private company.

  • What is Artax Biopharma’s current revenue?

    The current revenue for Artax Biopharma is .

  • How much funding has Artax Biopharma raised over time?

    Artax Biopharma has raised $48.5M.

  • Who are Artax Biopharma’s investors?

    , Dosbio50, Eli Lilly, Sound Bioventures, and Columbus Venture Partners are 5 of 9 investors who have invested in Artax Biopharma.

  • Who are Artax Biopharma’s competitors?

    Abivax, Meditope Biosciences, Equillium, Immunophotonics, and NexImmune are some of the 23 competitors of Artax Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »